Abstract
Psoriasis is a common cutaneous disease that can have a profound effect on an individual's life. New biologic drugs--proteins that are synthesized using recombinant DNA technology to mimic naturally occurring molecules and that selectively target the immune system--have changed the paradigm for treating this disease. We review 4 biologic drugs that are either currently FDA approved or in phase 3 studies: Alefacept (Amevive) and efalizumab (Raptiva), which are T-cell modulators; etanercept (Enbrel), a soluble TNF receptor; and infliximab (Remicade), an anti-TNF monoclonal antibody.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 34-36 |
| Number of pages | 3 |
| Journal | Minnesota medicine |
| Volume | 87 |
| Issue number | 3 |
| State | Published - Mar 2004 |
